You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 德琪醫藥(6996.HK)漲逾4% 產品管線取得重大進展
格隆匯 08-23 11:04
格隆匯8月23日丨德琪醫藥(6996.HK)漲逾4%,報12.22港元,總市值82億港元。8月20日晚間,德琪醫藥公佈中期業績,截至2021年6月30日止6個月,公司其他收入及收益為人民幣1813.5萬元,研發成本為1.35億元。2021年,公司的管線資產取得穩步進展,已於澳大利亞、韓國、新加坡及台灣提交塞利尼索治療復發/難治性多發性骨髓瘤和復發/難治性瀰漫大B細胞淋巴瘤及於中國內地及香港提交塞利尼索治療復發/難治性多發性骨髓瘤的NDA。截至2021年7月31日,公司有十五項正在中國內地、韓國、台灣和澳大利亞進行的臨牀研究,其中五項管線資產。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account